48 results found.
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Vericel Reports 3Q18 MACI Revenue of $16.4MM, +65.7% vs. 3Q17
Vericel posts another record quarter for MACI with revenue of US $16.4MM, +65.7% vs. 3Q...
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Vericel Posts 2Q18 MACI Revenue Growth
For 2Q18, Vericel posted MACI orthobiologic revenue of US $14.1MM, +9.3% vs. 2Q17, with 1H18 revenue of $26.2MM,...
1H18 Funding Recap: Where'd They All Go?
By Julie A. Vetalice Last year’s 1H review recapped 24 funding announcements. This year, we have 10 to cover. Ten! We'll leave speculation on that drop to more expert handlers. (If you want to share a thought on it, by all means, send me an 
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Vericel Closes $74.8MM Public Offering
Vericel closed its underwritten public offering of 5,750,000 shares of is common stock for $13/share, for gross proceeds o...
Vericel Prices $65MM Public Offering of Stock
Vericel, developer of MACI® autologous cultured chondrocytes for cartilage repair, priced its underwritten public offering of
Vericel Posts MACI 1Q18 Revenue Growth
For 1Q18, Vericel posted orthobiologic revenue of US $12.1MM, +142% vs. 1Q17.
Vericel's MACI Shows Sustained Benefit at Five Years
Study results demonstrated that improvements in pain and function from use of Vericel's MACI vs. microfracture in the treatment...
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Vericel Reports Orthobiologics Growth for 4Q17, 2017
Vericel posted 4Q17 orthobiologic revenue of US $16.1MM, +26.8% vs. 4Q16, and 2017 revenue of $43.9MM...
Vericel Receives First Payment from Innovative Cellular Collaboration
Vericel initiated its Carticel/MACI distribution agreement with Innovative Cellular Therapeutics following a
The Orthopaedic Products and Services of 2017
By Julie A. Vetalice The annual rundown of products and services is like attending a reunion—we’re looking back over the year and keeping you informed on what everyone is doing. Here’s what made headlines with market entry in 2017. We’ll start with services, and ...
Majority of Public Orthopaedic Companies Still on Track for Full-Year Guidance
By Julie A. Vetalice Looking at 3Q17 revenue and reading call transcripts, much was said about unforeseen headwinds that crept in before the close of the year, affecting orthopaedic companies in a variety of ways. Following weather events, oft-cited “softness&rdqu...
Vericel Reports 3Q17 MACI Revenue +19%
Vericel posted 3Q17 orthobiologic revenue of US $9.9MM, +19.3% vs. 3Q16, and YTD revenue of $27.8MM, +6.5% ...
Orthobiologics Activity Signals Collaborations and Clinical Data Essential for Company Growth
By Julie A. Vetalice ORTHOWORLD estimates that global orthobiologic product sales account for ~10% of the orthopaedic market’s revenue, overall. In 2016, that translated to just over $4.9 billion, an increase of 3% vs. 2015. For this year and into 2019, we’re projecting simi...
Sales Results for 20 Orthopaedic Companies: A Mid-year Status Report
By Julie A. Vetalice Now that we’ve collected 1H17 results from 20 publicly-traded companies, I’d like to share some performance-based observations. With now just 4 months remaining in the year, these companies provide a helpful gauge in projecting industry growth.
Vericel Reports 2Q17 Orthobiologic Revenue
Vericel posted 2Q17 orthobiologic revenue of US $12.9MM, +43.4% vs. 2Q16, and 1H17 revenue of $17.9MM, +27.9%
Public and Private Company Revenue Review: 1Q17
By Julie A. Vetalice We're eager to see 2Q17 results to prepare a 1H review for you. In the interim, here are the 1Q17 numbers for publicly-traded companies, with updates and estimates for a number of privately-traded companies, too. Exhibits 1 and 2 illustrate 1Q17 performanc...
Vericel Signs Distribution Agreement with Orsini Pharmaceutical
Vericel entered into a 2-year renewable agreement with Orsini Pharmaceutical for distribution of Cartice...
Vericel Reports 1Q17 Orthobiologic Revenue
Vericel posted 1Q17 orthobiologic revenue of US $5.0MM, -43.2% vs. 1Q16.
Vericel Licenses Products for Distribution in Southeast Asia
Vericel entered into a license agreement whereby Innovative Cellular Therapeutics will obtain exclusive righ...
Company Revenue 2016
For these publicly-traded orthopaedic device companies, Exhibits 1 and 2 present 2016 orthopaedic revenue and growth. Exhibit 1 includes links to company's full-year revenue reporting, as well. ...
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2018 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group